IDEXX Laboratories raised its full-year profit and revenue forecasts on Monday after reporting better third-quarter results than last year, as the pet diagnostics maker banks on owners spending more o... ...

Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ --Â Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will host a virtual fireside chat on Wednesday, November 5, 2025 at 11:00 am ET. Join Dwight Egan. CEO of Co-Dx, for an update on the Company's growth initiatives, including its recently announced definitive agreement with ...

Spectral AI Inc. (NASDAQ:MDAI) is one of the best AI stocks to buy under $20. On October 23, the company announced the pricing of a $7.6 million offering to bolster its balance sheet. The raising of additional capital should help support the expansion and development of the company’s DeepView System. Spectral AI Inc. (MDAI) Eyes $7.6M Capital Raise to Accelerate DeepView System Development In the offering, the company is to issue 4 million shares of common stock at $1.90 per share and corresponding warra ...

DALLAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the pricing of a $7.6 million offering. The offering will provide the Company with additional growth capital for the continued expansion and development of its DeepView® System. The transaction includes the issuance of 4,000,000 shares of its common st ...

交易概述 - Blackstone和TPG同意以高达183亿美元的交易收购医疗诊断公司Hologic [1] - 收购价格为每股76美元现金 对股票最后收盘价有近6%的溢价 [1] - 总潜在支付可能达到每股79美元 包含每股最高3美元的或有价值权 [2] 交易条款细节 - 股东有资格获得每股最高3美元的非交易性权利 取决于其乳腺健康业务在2026和2027财年达到特定全球收入目标 [2] - 交易预计在2026年上半年完成 [3] 市场反应与公司业务 - Hologic股价在盘前交易中上涨超过4% 交易曾短暂暂停 [2] - 公司专注于女性健康诊断 包括乳腺癌和宫颈癌筛查以及传染病检测 [2] 公司财务状况 - 公司分子诊断业务呈现稳定增长 并报告了乐观的财务业绩 [3] - 但公司指出其乳腺健康部门持续疲软 [3]

公司近期动态 - VolitionRx Limited及其子公司Volition Veterinary Diagnostics Development LLC宣布参与在弗吉尼亚海滩举行的HOPE AACR年度会议 [1] - 公司作为其企业社会责任战略的一部分，向HOPE AACR捐赠了Nu Q® Vet癌症检测产品，以支持为美国受危机和灾难影响的人们提供情感安慰的犬只 [1] 产品与技术 - Nu Q® Vet癌症检测适用于七岁及以上老年犬的常规预防性检查，或用于高风险品种的年轻犬 [3][9] - 该检测是非侵入性且具有成本效益的筛查工具，已在包括美国、英国、德国、日本等超过20个国家上市 [9] - 2024年，该产品的销售量超过10万次 [9] - 公司致力于通过其子公司开发和商业化简单、易用、经济有效的血液检测，以帮助诊断和监测一系列疾病，包括某些癌症以及与NETosis相关的疾病（如脓毒症） [11] 行业与市场 - Volition是一家跨国表观遗传学公司，专注于推进表观遗传学科学，致力于通过早期检测以及疾病和治疗监测来拯救生命和改善患有改变生命疾病的患者和动物的预后 [10] - 公司的研发活动主要集中在比利时，并在美国设有一个创新实验室和办公室，在伦敦设有办公室 [12] - 早期诊断和监测不仅有可能延长患者生命，还能改善其生活质量 [11] 合作与活动 - 公司通过捐赠Nu Q® Vet癌症检测来赞助HOPE AACR的活动 [3] - HOPE AACR是一个全志愿者非营利组织，拥有约300个响应团队，应对人为创伤、自然灾害等灾难 [6] - 公司鼓励参与免费的DVM360网络研讨会，以了解支持Nu Q® Vet的临床证据、如何处理样本、解读结果等 [5]

*The Co-Dx PCR platform (including the Co-Dx PCR Homeâ"¢, Co-Dx PCR Proâ"¢, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. Accessibility StatementSkip Navigation New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- Co-Diagno ...

公司财务信息发布安排 - Veracyte公司计划于2025年11月4日星期二市场收盘后发布2025年第三季度财务业绩 [1] - 公司管理层将于同日下午4:30（美国东部时间）举行电话会议和网络直播 讨论财务业绩并提供一般业务更新 [1] - 电话会议的网络直播将在公司网站上进行 [1]

Reported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational EfficiencyEarnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), ("Biomerica" or the "Company") a global provider of advan ...

融资活动概述 - 公司于2025年10月10日完成一项非公开发行，发行了2,250,000股普通股（或其替代的预融资认股权证）以及可认购最多4,500,000股普通股的F系列认股权证，发行价格为每股2.00美元 [1] - F系列认股权证的行权价为每股1.75美元，可立即行使，有效期为发行日后五年半 [1] - 本次发行的总收益（扣除费用前）为450万美元 [2] 资金用途与业务重点 - 发行净收益计划用于获取FDA批准相关事宜（包括相关临床研究）、其他研发活动以及一般营运资金需求 [2] - 公司专注于通过其Symphony系统改善患者预后，该系统是一种经济高效、快速的近患者检测系统，用于脓毒症分诊和疾病进展监测 [5] - 公司的首个候选产品是用于脓毒症的IL-6检测，旨在提供约20分钟的“样本到结果”检测，以帮助医疗专业人员更早做出更好的分诊/治疗决策 [5] 发行相关安排 - Rodman and Renshaw LLC担任此次发行的独家配售代理 [2] - 本次发行依据1933年证券法第4(a)(2)条和/或D条例进行，所发行证券及认股权证对应的普通股未根据证券法或适用的州证券法进行注册 [3] - 根据与投资者签订的注册权协议，公司同意提交一份涵盖上述证券的转售注册声明 [3]